Micromet (MITI) surges 34% to $11.07, which is just above Amgen's (AMGN) $11/share offer for the company.
|Jan. 26, 2012, 8:35 AM|1 Comment
Jan. 26, 2012, 8:20 AM
More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday. (PR)
|Jan. 26, 2012, 8:20 AM
Jan. 26, 2012, 8:08 AM
Amgen (AMGN) agrees to acquire Micromet (MITI) for $11/share, or $1.16B. (PR)